Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Clinical studies using higher doses have reported similar safety levels
It should not replace first-line, evidence-based treatment for any GI condition
In a meta-analysis, subcutaneous semaglutide demonstrated superior efficacy in reducing glycated hemoglobin when compared to other antidiabetic drugs, without increasing the rate of hypoglycemia
Not intended for human dosing, injection, or ingestion
US$ 26.61
US$ 22.20
US$ 29.45
US$ 26.15
US$ 29.25
US$ 26.89
US$ 23.81
